CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate | Zendy

Zhen Shen | Zendy; Baixing Ding | Zendy; Yingmin Bi | Zendy; Shi Wu | Zendy; Su Xu | Zendy; Xiaogang Xu | Zendy; Qinglan Guo | Zendy; Minggui Wang | Zendy

Open Access

CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate

Author(s) -

Zhen Shen,

Baixing Ding,

Yingmin Bi,

Shi Wu,

Su Xu,

Xiaogang Xu,

Qinglan Guo,

Minggui Wang

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01848-16

Subject(s) - sulbactam , escherichia coli , tazobactam , cefotaxime , microbiology and biotechnology , biology , plasmid , antibiotics , dna , antibiotic resistance , gene , biochemistry , imipenem

A novel β-lactamase, CTX-M-190, derived from CTX-M-55 by a single substitution of Ser for Thr at position 133 (Ser133Thr), was identified in a natural Escherichia coli clinical isolate. CTX-M-190 exhibited potent hydrolytic activity against cefotaxime, with a k cat /K m ratio of 14.5 μM -1 s -1 , and was highly resistant to inhibition by the β-lactamase inhibitors tazobactam and sulbactam, whose 50% inhibitory concentrations were 77- and 55-fold higher, respectively, for CTX-M-190 than for CTX-M-55. bla CTX-M-190 was located within the genetic platform ISEcp1-bla CTX-M -orf477, which was harbored by a 70-kb IncI1 plasmid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research